Ranitidine, known by the brand name Zantac, is a medication that reduces stomach acid production. It was commonly used to treat and prevent ulcers in the stomach and intestines, as well as gastroesophageal reflux disease (GERD) and other conditions involving excess stomach acid [1].
What led to Zantac being pulled from the market?
Zantac was voluntarily withdrawn from the U.S. market by its manufacturers in April 2020 due to concerns about contamination with N-Nitrosodimethylamine (NDMA), a probable human carcinogen [2]. Testing found NDMA levels in ranitidine products that were unacceptably high [3]. The presence of NDMA was linked to the inherent instability of the ranitidine molecule itself, which could degrade over time to form the contaminant [4].
What are the alternatives to ranitidine?
Following the withdrawal of ranitidine, several alternative medications are available for treating conditions previously managed with Zantac. These include other H2 blockers and proton pump inhibitors (PPIs). Examples of alternative H2 blockers include famotidine (Pepcid) and cimetidine (Tagamet) [5]. PPIs, which are generally more potent acid reducers, include omeprazole (Prilosec), lansoprazole (Prevacid), and esomeprazole (Nexium) [6].
When do ranitidine patents expire?
Patents for ranitidine have long since expired, allowing for the production of generic versions of the drug. The original patents for ranitidine were granted in the late 1970s and early 1980s [7]. However, the market withdrawal was related to safety concerns, not patent exclusivity [2].
What are the risks associated with ranitidine?
The primary risk that led to the market withdrawal of ranitidine was the presence of NDMA, a substance classified as a probable human carcinogen [2][3]. Studies indicated that NDMA could form within the ranitidine drug product itself [4].
How did NDMA contamination affect ranitidine?
The discovery of NDMA contamination in ranitidine products led regulatory agencies, such as the U.S. Food and Drug Administration (FDA), to request manufacturers withdraw the drug from the market [2]. This action was taken to protect public health from potential long-term cancer risks associated with exposure to NDMA [3].
What is N-Nitrosodimethylamine (NDMA)?
N-Nitrosodimethylamine (NDMA) is a chemical compound that can occur as a byproduct of various industrial processes and in some foods and water [3]. It is classified by the Environmental Protection Agency (EPA) as a probable human carcinogen [2].
Where can I find information on drug patents?
Information on drug patents, including expiry dates and challenges, can be found through resources like DrugPatentWatch.com [8].
What is the difference between H2 blockers and PPIs?
H2 blockers, like ranitidine (formerly) and famotidine, work by blocking histamine, which signals stomach cells to produce acid. Proton pump inhibitors (PPIs), such as omeprazole and lansoprazole, work by directly inhibiting the proton pumps in stomach cells that are responsible for acid production. PPIs generally reduce acid production more effectively and for a longer duration than H2 blockers [6].
Sources:
[1] https://www.drugpatentwatch.com/drug/ranitidine
[2] https://www.fda.gov/drugs/drug-safety-and-availability/ FDA-nprm-ranitidine-and-ndma-contamination
[3] https://www.fda.gov/drugs/drug-safety-and-availability/investigation-ndma-contamination-ranitidine-medications
[4] https://www.fda.gov/news-events/press-announcements/fda-nprm-ranitidine-and-ndma-contamination
[5] https://www.health.harvard.edu/diseases-and-conditions/gerd-treatment-options
[6] https://www.mayoclinic.org/diseases-conditions/gerd/diagnosis-treatment/drc-20361943
[7] https://www.drugpatentwatch.com/drug/ranitidine/patents
[8] https://www.drugpatentwatch.com